Literature DB >> 19002608

A detrimental role for IgG and FcgammaR in Leishmania mexicana infection.

Laurence U Buxbaum1.   

Abstract

The intracellular protozoan parasite Leishmania causes leishmaniasis, which is the second biggest killer worldwide among parasitic diseases, after malaria. As drug therapy for leishmaniasis is toxic and resistance is growing, a vaccine is an important weapon against this disease. Unfortunately, no effective vaccine exists for any human parasitic infection. Worse yet, nearly all effective vaccines whose mechanisms are known work through the induction of protective antibodies. Leishmania mexicana causes primarily chronic cutaneous disease. Not only are antibodies not effective at killing Leishmania, as it hides inside the parasitophorous vacuole of the host cell, but new research indicates that IgG antibodies may be crucial in suppressing the host immune response by generating an immunosuppressive interleukin-10 response. IL-10 is able to decrease the needed Th1-generated IFN-gamma and downregulates production of nitric oxide, a required effector mechanism of parasite killing. We have been studying the pathways that the host uses to partially control L. mexicana infection, which include STAT4, IFN-gamma, and inducible nitric oxide synthase, but found that the IL-12 pathway is suppressed by IL-10. We are now studying the mechanisms by which IgG, bound to parasites, can induce IL-10 through FcgammaR ligation and how this suppresses a healing immune response. We are examining which IgG isotypes bind to which FcgammaRs and whether macrophages are the necessary source of IL-10 for chronic disease. Elucidation of these mechanisms may help us to design vaccines that will not induce antibody-mediated immunosuppressive IL-10 responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19002608     DOI: 10.1007/s12026-008-8074-5

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  50 in total

1.  Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice.

Authors:  W L Hazenbos; J E Gessner; F M Hofhuis; H Kuipers; D Meyer; I A Heijnen; R E Schmidt; M Sandor; P J Capel; M Daëron; J G van de Winkel; J S Verbeek
Journal:  Immunity       Date:  1996-08       Impact factor: 31.745

2.  Interleukin 10- and Fcgamma receptor-deficient mice resolve Leishmania mexicana lesions.

Authors:  Laurence U Buxbaum; Phillip Scott
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

3.  Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production.

Authors:  C M Snapper; W E Paul
Journal:  Science       Date:  1987-05-22       Impact factor: 47.728

4.  Interleukin-10-deficient mice develop chronic enterocolitis.

Authors:  R Kühn; J Löhler; D Rennick; K Rajewsky; W Müller
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

5.  Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16).

Authors:  W L Hazenbos; I A Heijnen; D Meyer; F M Hofhuis; C R Renardel de Lavalette; R E Schmidt; P J Capel; J G van de Winkel; J E Gessner; T K van den Berg; J S Verbeek
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

6.  Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice.

Authors:  F P Heinzel; R M Rerko; F Ahmed; E Pearlman
Journal:  J Immunol       Date:  1995-07-15       Impact factor: 5.422

7.  Differences in expression and exposure of promastigote and amastigote membrane molecules in Leishmania tropica.

Authors:  M D Sadick; H V Raff
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

8.  Differential regulation of the interleukin-12 receptor during the innate immune response to Leishmania major.

Authors:  D Jones; M M Elloso; L Showe; D Williams; G Trinchieri; P Scott
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

9.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

10.  CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis.

Authors:  Charles F Anderson; Mohammed Oukka; Vijay J Kuchroo; David Sacks
Journal:  J Exp Med       Date:  2007-02-05       Impact factor: 14.307

View more
  16 in total

1.  Promotion of a functional B cell germinal center response after Leishmania species co-infection is associated with lesion resolution.

Authors:  Katherine N Gibson-Corley; Paola M Boggiatto; Marie M Bockenstedt; Christine A Petersen; Thomas J Waldschmidt; Douglas E Jones
Journal:  Am J Pathol       Date:  2012-03-17       Impact factor: 4.307

2.  Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.

Authors:  Beatriz Coutinho De Oliveira; Malcolm S Duthie; Valéria Rêgo Alves Pereira
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

Review 3.  Cytokines and their STATs in cutaneous and visceral leishmaniasis.

Authors:  Hannah E Cummings; Rashmi Tuladhar; Abhay R Satoskar
Journal:  J Biomed Biotechnol       Date:  2010-03-15

4.  Antineoplastic drug, carboplatin, protects mice against visceral leishmaniasis.

Authors:  Tejinder Kaur; Prerna Makkar; Kulbir Randhawa; Sukhbir Kaur
Journal:  Parasitol Res       Date:  2012-09-09       Impact factor: 2.289

Review 5.  Potential biomarkers of immune protection in human leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

Review 6.  Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes.

Authors:  Scott B Halstead; Suresh Mahalingam; Mary A Marovich; Sukathida Ubol; David M Mosser
Journal:  Lancet Infect Dis       Date:  2010-10       Impact factor: 25.071

7.  BALB/c mice deficient in CD4 T cell IL-4Rα expression control Leishmania mexicana Load although female but not male mice develop a healer phenotype.

Authors:  Karen J Bryson; Owain R Millington; Thabang Mokgethi; H Adrienne McGachy; Frank Brombacher; James Alexander
Journal:  PLoS Negl Trop Dis       Date:  2011-01-04

Review 8.  Immune Responses in Leishmaniasis: An Overview.

Authors:  Ana Caroline Costa-da-Silva; Danielle de Oliveira Nascimento; Jesuino R M Ferreira; Kamila Guimarães-Pinto; Leonardo Freire-de-Lima; Alexandre Morrot; Debora Decote-Ricardo; Alessandra Almeida Filardy; Celio Geraldo Freire-de-Lima
Journal:  Trop Med Infect Dis       Date:  2022-03-31

9.  Clinical and Immunological Analysis of Cutaneous Leishmaniasis before and after Different Treatments.

Authors:  José A O'Daly; Humberto M Spinetti; Joe Gleason; María B Rodríguez
Journal:  J Parasitol Res       Date:  2013-06-13

10.  An in vitro model of antibody-enhanced killing of the intracellular parasite Leishmania amazonensis.

Authors:  Katherine N Gibson-Corley; Marie M Bockenstedt; Huijuan Li; Paola M Boggiatto; Yashdeep Phanse; Christine A Petersen; Bryan H Bellaire; Douglas E Jones
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.